Skip to main content
Figure 2 | BMC Chemical Biology

Figure 2

From: Glycosylated VCAM-1 isoforms revealed in 2D western blots of HUVECs treated with tumoral soluble factors of breast cancer cells

Figure 2

Expression of VCAM-1 cell content is increased when HUVECs are treated with TSFZR75.30 and decreased when cells are pre-treated with tunicamycin. A) Exon maps of VCAM-1a: 739 amino acid, 9 exons and 6 N-glycosylation sites and, VCAM-1b: 647 residues, lacking exon 5 and the 2nd N-glycosylation site (hexagons). B) Western blot to detect VCAM-1 in twenty micrograms of total extracts from HUVECs treated for 3 hr with TNF or TSFZR75.30 (lanes 3,5) or pre-treated with tunicamycin 3 h before TNF or TSF's (lanes 4,6). C) Histogram of the mean of three individual experiments and the normalized densitometric values reflecting expression of the VCAM-1 isoforms: a, b and x with respect to actin signal. p < 0.001 (*) compared control. The error bars indicate ± standard error of the mean.

Back to article page